source
- BMS drops Orum’s targeted degrader after Phase 1 resultsBMS announced it is ending development of ORM-6151, a degrader‑antibody conjugate acquired from Orum Therapeutics. The decision follows a Phase 1 trial in acute myeloid leukemia and myelodysplasti…
- FDA faces nominee hearing, hiring woes and reviews of psychedelics and testosterone therapiesA Senate committee set a hearing for President Trump's pick to lead the FDA, highlighting the political scrutiny of the agency's top leadership. New reporting reveals ongoing hiring challenges at…